BACKGROUND: Colorectal cancer (CRC) is a common life-threatening malignancy; risk and progression are elevated in obesity. The purpose of this study was to measure the frequency of circulating CD34-positive endothelial and progenitor cells in the circulation and evaluate their potential values as CRC biomarkers. METHODS: Blood was collected from 45 patients with CRC and compared with cancer-free control donors. Detection and enumeration of cells was carried out by flow cytometry on the basis of immunophenotypes established for the cell populations of interest: hematopoietic and endothelial circulating progenitor cells, endothelial cells, mesenchymal stromal cells (MSC), and CD34bright leukocytes (CD34b LC). Groups were compared using multivariate regression analysis. Receiver-operating characteristic (ROC) curve analysis was used to evaluate the diagnostic values. RESULTS: After adjusting for age and body mass index (BMI), the mean frequencies of MSCs and CD34b LCs were significantly higher in the circulation of patients with CRC than in controls. The areas under the ROC curve were 0.77 and 0.82 for MSCs and CD34b LCs, respectively. The frequency of circulating MSCs, but not of the other cell populations, was also found to be significantly higher in the circulation of obese patients with CRC (BMI ≥ 30 kg/m(2)) than in lean patients with CRC and obese controls. CONCLUSIONS: Increased frequency of MSCs and CD34b LCs in the peripheral blood may represent a new diagnostic marker for CRC. IMPACT: BMI-dependent changes in circulating MSCs, potentially mobilized from white adipose tissue may reveal their trafficking to tumors, which could be one of the mechanistic links between obesity and cancer progression.
BACKGROUND:Colorectal cancer (CRC) is a common life-threatening malignancy; risk and progression are elevated in obesity. The purpose of this study was to measure the frequency of circulating CD34-positive endothelial and progenitor cells in the circulation and evaluate their potential values as CRC biomarkers. METHODS: Blood was collected from 45 patients with CRC and compared with cancer-free control donors. Detection and enumeration of cells was carried out by flow cytometry on the basis of immunophenotypes established for the cell populations of interest: hematopoietic and endothelial circulating progenitor cells, endothelial cells, mesenchymal stromal cells (MSC), and CD34bright leukocytes (CD34b LC). Groups were compared using multivariate regression analysis. Receiver-operating characteristic (ROC) curve analysis was used to evaluate the diagnostic values. RESULTS: After adjusting for age and body mass index (BMI), the mean frequencies of MSCs and CD34b LCs were significantly higher in the circulation of patients with CRC than in controls. The areas under the ROC curve were 0.77 and 0.82 for MSCs and CD34b LCs, respectively. The frequency of circulating MSCs, but not of the other cell populations, was also found to be significantly higher in the circulation of obesepatients with CRC (BMI ≥ 30 kg/m(2)) than in lean patients with CRC and obese controls. CONCLUSIONS: Increased frequency of MSCs and CD34b LCs in the peripheral blood may represent a new diagnostic marker for CRC. IMPACT: BMI-dependent changes in circulating MSCs, potentially mobilized from white adipose tissue may reveal their trafficking to tumors, which could be one of the mechanistic links between obesity and cancer progression.
Authors: A Woywodt; A D Blann; T Kirsch; U Erdbruegger; N Banzet; M Haubitz; F Dignat-George Journal: J Thromb Haemost Date: 2006-03 Impact factor: 5.824
Authors: Mervin C Yoder; Laura E Mead; Daniel Prater; Theresa R Krier; Karim N Mroueh; Fang Li; Rachel Krasich; Constance J Temm; Josef T Prchal; David A Ingram Journal: Blood Date: 2006-10-19 Impact factor: 22.113
Authors: P Anderlini; D Przepiorka; C Seong; T L Smith; Y O Huh; J Lauppe; R Champlin; M Körbling Journal: Transfusion Date: 1997-05 Impact factor: 3.157
Authors: Rose Du; Kan V Lu; Claudia Petritsch; Patty Liu; Ruth Ganss; Emmanuelle Passegué; Hanqiu Song; Scott Vandenberg; Randall S Johnson; Zena Werb; Gabriele Bergers Journal: Cancer Cell Date: 2008-03 Impact factor: 31.743
Authors: Paul Beaudry; Jeremy Force; George N Naumov; Andrew Wang; Cheryl H Baker; Anderson Ryan; Shay Soker; Bruce E Johnson; Judah Folkman; John V Heymach Journal: Clin Cancer Res Date: 2005-05-01 Impact factor: 12.531
Authors: Emily M Chandler; Bo Ri Seo; Joseph P Califano; Roberto C Andresen Eguiluz; Jason S Lee; Christine J Yoon; David T Tims; James X Wang; Le Cheng; Sunish Mohanan; Mark R Buckley; Itai Cohen; Alexander Yu Nikitin; Rebecca M Williams; Delphine Gourdon; Cynthia A Reinhart-King; Claudia Fischbach Journal: Proc Natl Acad Sci U S A Date: 2012-06-04 Impact factor: 11.205
Authors: Ann H Klopp; Yan Zhang; Travis Solley; Felipe Amaya-Manzanares; Frank Marini; Michael Andreeff; Bisrat Debeb; Wendy Woodward; Rosemarie Schmandt; Russell Broaddus; Karen Lu; Mikhail G Kolonin Journal: Clin Cancer Res Date: 2011-12-13 Impact factor: 12.531
Authors: Amelie G Ramirez; Dorothy Long Parma; Edgar Muñoz; Kristin D Mendoza; Crystel Harb; Alan E C Holden; Michael Wargovich Journal: Contemp Clin Trials Date: 2017-03-22 Impact factor: 2.226
Authors: Caroline Himbert; Mahmoud Delphan; Dominique Scherer; Laura W Bowers; Stephen Hursting; Cornelia M Ulrich Journal: Cancer Prev Res (Phila) Date: 2017-09
Authors: Amy L Strong; Julie A Semon; Thomas A Strong; Tatyana T Santoke; Shijia Zhang; Harris E McFerrin; Jeffrey M Gimble; Bruce A Bunnell Journal: Stem Cells Date: 2012-12 Impact factor: 6.277